141 related articles for article (PubMed ID: 9083515)
1. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis.
Manetto V; Lorenzini R; Cordon-Cardo C; Krajewski S; Rosai J; Reed JC; Eusebi V
Virchows Arch; 1997 Feb; 430(2):125-30. PubMed ID: 9083515
[TBL] [Abstract][Full Text] [Related]
2. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland.
Branet F; Brousset P; Krajewski S; Schlaifer D; Selves J; Reed JC; Caron P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2726-30. PubMed ID: 8675602
[TBL] [Abstract][Full Text] [Related]
3. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
4. Bag-1 expression in thyroid neoplasm: its correlation with Bcl-2 expression and carcinoma dedifferentiation.
Ito Y; Yoshida H; Nakano K; Takamura Y; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2003; 23(1B):569-76. PubMed ID: 12680148
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
6. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
7. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
8. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
9. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland.
Pilotti S; Collini P; Rilke F; Cattoretti G; Del Bo R; Pierotti MA
J Pathol; 1994 Apr; 172(4):337-42. PubMed ID: 8207614
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
12. [Bcl-2 proto-oncogene expression in neoplastic and non neoplastic thyroid tissue].
Branet F; Caron P; Camallières M; Selves J; Brousset P
Bull Cancer; 1996 Mar; 83(3):213-7. PubMed ID: 8695923
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.
Wang DG; Liu WH; Johnston CF; Sloan JM; Buchanan KD
Am J Pathol; 1998 Jun; 152(6):1407-13. PubMed ID: 9626044
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of Bcl-2, Bcl-x, and Bax in follicular carcinomas of the thyroid.
Haynik DM; Prayson RA
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):417-21. PubMed ID: 17122638
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid.
Cvejic D; Selemetjev S; Savin S; Paunovic I; Petrovic I; Tatic S
Pathology; 2008 Aug; 40(5):475-80. PubMed ID: 18604733
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and western blot study.
Rochaix P; Monteil-Onteniente S; Rochette-Egly C; Caratero C; Voigt JJ; Jozan S
Histopathology; 1998 Oct; 33(4):337-43. PubMed ID: 9822923
[TBL] [Abstract][Full Text] [Related]
17. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas.
Pollina L; Pacini F; Fontanini G; Vignati S; Bevilacqua G; Basolo F
Br J Cancer; 1996 Jan; 73(2):139-43. PubMed ID: 8546897
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of expression of bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland.
Mitselou A; Peschos D; Dallas P; Charalabopoulos K; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2004 Dec; 26(4):282-6. PubMed ID: 15627060
[TBL] [Abstract][Full Text] [Related]
19. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
20. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
